For many years, pharmaceutical packaging teams faced a familiar challenge: individual standards and test methods existed, but clear guidance on how those elements fit together was limited. USP chapters described *what* tests could be performed, but rarely explained *when*, *why*, or *in what sequence* they should be applied.

USP <1031> was introduced to address this exact gap. Rather than functioning as another testing chapter, USP <1031> provides a **decision framework** for evaluating the biocompatibility of materials used in pharmaceutical packaging systems. Its purpose is not to mandate additional testing, but to ensure that biological evaluation is driven by exposure, chemistry, and patient risk—rather than by legacy checklists.

Why USP <1031> Matters for Packaging

Pharmaceutical packaging occupies a unique regulatory space. Unlike medical devices or implants, packaging materials are not intended to contact patient tissue directly. Instead, any potential risk is mediated through chemical migration into the drug product, followed by patient exposure via the intended route of administration.

Historically, this distinction was not always reflected in testing strategies. Packaging materials were often evaluated using broad biological tests originally developed for devices, leading to conservative but poorly targeted testing programs.

USP <1031> explicitly recognizes this reality. It frames packaging biocompatibility around **exposure pathways**, making it clear that the goal is not to test materials in isolation, but to evaluate whether substances that may migrate into a drug product pose a meaningful risk to patients.

The Core Elements of the USP <1031> Framework

USP <1031> integrates three complementary pillars:

First, **in vitro biological screening**, typically performed under USP <87>, is used to identify overt biological reactivity. These assays provide an early indication of whether a material or extract exhibits cytotoxic or other adverse biological responses.

Second, **chemical characterization** is used to identify and, where appropriate, quantify substances that may migrate from packaging materials into the drug product. This step anchors the evaluation in material science and real-world exposure potential.

Third, **toxicological risk assessment** translates chemical data into patient-relevant risk. By considering dose, duration, route of administration, and established safety thresholds, toxicology provides the context needed to determine whether identified substances present an actual concern.

These elements are not intended to operate independently. USP <1031> emphasizes that meaningful conclusions emerge only when biological, chemical, and toxicological data are interpreted together.

How USP <1031> Changes Test Selection

One of the most important contributions of USP <1031> is its impact on test selection. Rather than treating biological tests as prerequisites, the chapter positions them as tools to resolve specific uncertainties.

For example, if chemical characterization demonstrates low extractable burden and toxicological assessment confirms adequate safety margins, additional biological testing may not be warranted. Conversely, if in vitro screening under USP <87> identifies unexpected biological reactivity, further investigation may be appropriate, even if chemical data alone appear benign.

This logic supports both **test selection and test omission**, provided decisions are scientifically justified and well documented.

Escalation to In Vivo Testing: A Last Resort

USP <1031> is explicit that escalation to in vivo testing, such as USP <88>, should occur only when lower-tier evaluations cannot adequately address uncertainty.

This represents a meaningful departure from historical practice, where in vivo testing was often performed preemptively. Under the USP <1031> framework, animal testing becomes a targeted, problem-solving step rather than a default requirement.

For packaging teams, this clarification provides a defensible basis for minimizing animal testing while maintaining patient safety and regulatory confidence.

Common Misunderstandings Around USP <1031>

As organizations begin to adopt USP <1031>, several misunderstandings are emerging:

  • Viewing USP <1031> as an additional testing requirement rather than a framework
    • Treating chemical characterization and toxicology as optional or secondary
    • Applying device-style biocompatibility logic to packaging materials
    • Assuming USP <1031> eliminates the need for biological testing entirely

USP <1031> does none of these things. Instead, it clarifies how existing tools should be applied more intelligently.

Practical Implications for Packaging Programs

When applied correctly, USP <1031> offers tangible benefits:

– Clear justification for why specific tests were selected or omitted
– Improved alignment between biology, chemistry, and exposure
– Reduced reliance on unnecessary in vivo testing
– Stronger audit narratives grounded in scientific reasoning
– Greater flexibility during material changes and supplier transitions

Perhaps most importantly, USP <1031> helps packaging teams move from reactive testing to **proactive risk management**.

Positioning USP <1031> for the 2026 Transition

As revised USP chapters become effective in December 2026, organizations that fail to adopt the USP <1031> framework risk clinging to outdated testing paradigms. This can result in unnecessary testing, longer timelines, and avoidable cost.

By contrast, teams that align early with USP <1031> establish a clear, defensible approach to biocompatibility that scales across materials, dosage forms, and lifecycle changes.

The Takeaway

USP <1031> is not about adding complexity, it is about adding clarity.

For pharmaceutical packaging teams, it provides the missing decision logic that connects USP <87>, chemical characterization, toxicology, and USP <88> into a coherent, risk-based strategy. Applied correctly, it enables smarter testing decisions, stronger regulatory positioning, and better outcomes for both patients and organizations.